| 4.11 -0.39 (-8.67%) | 09-10 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 5.47  |
1-year : | 5.88 |
| Resists | First : | 4.68 |
Second : | 5.03 |
| Pivot price | 4.51 |
|||
| Supports | First : | 4.11 |
Second : | 3.41 |
| MAs | MA(5) : | 4.43 |
MA(20) : | 4.55 |
| MA(100) : | 4.62 |
MA(250) : | 4.06 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 18.5 |
D(3) : | 26.1 |
| RSI | RSI(14): 36.1 |
|||
| 52-week | High : | 5.88 | Low : | 2.66 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ATHE ] has closed below the lower bollinger band by 25.5%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ ATHE ] is to continue within current trading range. It is unclear right now based on current values. 47.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 13 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.47 - 4.5 | 4.5 - 4.52 |
| Low: | 4.05 - 4.08 | 4.08 - 4.11 |
| Close: | 4.07 - 4.12 | 4.12 - 4.15 |
Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease. The company is also advancing PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease. Established in 1997, the entity was formerly known as Prana Biotechnology Limited before rebranding to Alterity Therapeutics Limited in April 2019, and its main operations are based in Melbourne, Australia.
Wed, 09 Sep 2026
ALTERITY THERAPEUTICS LTD (NASDAQ: ATHE) Director Acquires 47,620 Shares at $0.50 Each - Kalkine Media
Tue, 08 Sep 2026
Alterity Therapeutics (ATHE) director adds 47K shares - stocktitan.net
Tue, 08 Sep 2026
ATHE Form 4 Filings - Alterity Therapeutics Ltd SEC Form 4 - stocktitan.net
Tue, 08 Sep 2026
Alterity Therapeutics (ATHE) CEO sheds 47,620 stock options - stocktitan.net
Tue, 08 Sep 2026
Alterity Therapeutics (NASDAQ: ATHE) issues new shares tied to options—how big is the deal? - stocktitan.net
Tue, 08 Sep 2026
[6-K] ALTERITY THERAPEUTICS LTD Current Report (Foreign Issuer) - stocktitan.net
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 18 (M) |
| Held by Insiders | 1.45e+007 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 38 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.509e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 816.1 % |
| Return on Equity (ttm) | -34.1 % |
| Qtrly Rev. Growth | 3.61e+006 % |
| Gross Profit (p.s.) | 0.35 |
| Sales Per Share | 0.36 |
| EBITDA (p.s.) | -0.97 |
| Qtrly Earnings Growth | -1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -23 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 11.22 |
| Price to Cash Flow | -0.1 |
| Dividend | 0 |
| Forward Dividend | 24760 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|